Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alar Pharmaceuticals's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was NT$-0.53.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was NT$-1.69.
During the past 12 months, Alar Pharmaceuticals's average earnings per share (NRI) Growth Rate was -2512.90% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -50.40% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Alar Pharmaceuticals's EPS without NRI or its related term are showing as below:
ROCO:6785'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.4 Med: 11.4 Max: 40.2
Current: -50.4
During the past 9 years, Alar Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 40.20% per year. The lowest was -50.40% per year. And the median was 11.40% per year.
ROCO:6785's 3-Year EPS without NRI Growth Rate is ranked worse than 94.92% of 788
companies
in the Drug Manufacturers industry
Industry Median: 9.65
vs ROCO:6785: -50.40
Alar Pharmaceuticals's EPS (Basic) for the
three
months ended in Mar. 2026 was NT$-0.53.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was NT$-1.70.
Alar Pharmaceuticals (ROCO:6785) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Alar Pharmaceuticals EPS without NRI Related Terms
Alar Pharmaceuticals EPS without NRI Historical Data
* Premium members only.
The historical data trend for Alar Pharmaceuticals's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6785 vs ZTS, UTHR: EPS without NRI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alar Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alar Pharmaceuticals PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alar Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Alar Pharmaceuticals's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1.69
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alar Pharmaceuticals (ROCO:6785) has a EPS without NRI of NT$-1.69 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Alar Pharmaceuticals and its competitors. According to the industry distribution chart, Alar Pharmaceuticals ranks #748 out of 788 companies in the Drug Manufacturers industry, placing it in the top 94.9%.
Is Alar Pharmaceuticals' EPS without NRI too high?
Alar Pharmaceuticals' current EPS without NRI is NT$-1.69. Based on the distribution chart, Alar Pharmaceuticals ranks #748 out of 788 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alar Pharmaceuticals has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alar Pharmaceuticals' EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alar Pharmaceuticals ranks #748 out of 788 companies for EPS without NRI. This places Alar Pharmaceuticals in the lower half of its industry. The industry median EPS without NRI is 9.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.65, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Alar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alar Pharmaceuticals's current EPS without NRI is NT$-1.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alar Pharmaceuticals (ROCO:6785) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$96.24, compared to a current price of NT$108.50 — trading 12.7% above its estimated fair value. The current EPS without NRI is NT$-1.69. Alar Pharmaceuticals' overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Alar Pharmaceuticals (ROCO:6785), the current EPS without NRI is NT$-1.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alar Pharmaceuticals (ROCO:6785) Overvalued in 2026?
Based on GuruFocus' analysis, Alar Pharmaceuticals stock appears to be overvalued.
The current stock price of NT$108.50 is trading 12.7% above its estimated GF Value™ of NT$96.24.
GuruFocus considers Alar Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ROCO:6785:
EPS without NRI: NT$-1.69
GF Value™: NT$96.24 vs. price of NT$108.50 (12.7% above fair value)
No single metric tells the full story. See the ROCO:6785 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
53GF Score
Get the complete analysis for ROCO:6785
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6785 has been successfully added to your 
